It can be hypothesized that STS patients might benefit from both upstream inhibitors of β-catenin, such as PORCN inhibitors or WNT ligand-receptor interaction inhibitors, as well as downstream inhibitors of β-catenin, both of which have shown promising results in clinical treatments of neoplasms of epithelial origin. Here, PORCN is linked to telomere syndrome.